• Je něco špatně v tomto záznamu ?

Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents

F. Millot, J. Guilhot, M. Suttorp, AM. Güneş, P. Sedlacek, E. De Bont, CK. Li, K. Kalwak, B. Lausen, S. Culic, M. Dworzak, E. Kaiserova, B. De Moerloose, F. Roula, A. Biondi, A. Baruchel,

. 2017 ; 102 (10) : 1704-1708. [pub] 20170824

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024710

The EUTOS Long-Term Survival score was tested in 350 children with chronic myeloid leukemia in first chronic phase treated with imatinib and registered in the International Registry for Childhood Chronic Myeloid Leukemia. With a median follow up of 3 years (range, 1 month to 6 years) progression and/or death (whichever came first) occurred in 23 patients. For the entire cohort of patients the 5-year progression-free survival rate was 92% (95% CI: 87%-94%) and the 5-year survival accounting for chronic myeloid leukemia deaths was 97% (95% CI: 94%-99%). Of the 309 patients allocated to low (n=199), intermediate (n=68) and high (n=42) risk groups by the EUTOS Long-Term Survival score, events (progression and/or death) occurred in 6.0%, 8.8% and 26.2%, respectively. Estimates of the 5-year progression-free survival rates according to these three risk groups were 96% (95% CI: 92%-98%), 88% (95% CI: 76%-95%) and 67% (95% CI: 48%-81%), respectively. Differences in progression-free survival according to these risk groups were highly significant (P<0.0001, overall). The EUTOS Long-Term Survival score showed better differentiation of progression-free survival than the Sokal (<45 years), Euro and EUTOS scores in children and adolescents with chronic myeloid leukemia and should be considered in therapeutic algorithms. (Trial registered at: www.clinicaltrials.gov NCT01281735).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024710
003      
CZ-PrNML
005      
20180716095527.0
007      
ta
008      
180709s2017 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2017.170035 $2 doi
035    __
$a (PubMed)28838993
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Millot, Frédéric $u Inserm CIC 1402, University Hospital, Poitiers, France f.millot@chu-poitiers.fr.
245    10
$a Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents / $c F. Millot, J. Guilhot, M. Suttorp, AM. Güneş, P. Sedlacek, E. De Bont, CK. Li, K. Kalwak, B. Lausen, S. Culic, M. Dworzak, E. Kaiserova, B. De Moerloose, F. Roula, A. Biondi, A. Baruchel,
520    9_
$a The EUTOS Long-Term Survival score was tested in 350 children with chronic myeloid leukemia in first chronic phase treated with imatinib and registered in the International Registry for Childhood Chronic Myeloid Leukemia. With a median follow up of 3 years (range, 1 month to 6 years) progression and/or death (whichever came first) occurred in 23 patients. For the entire cohort of patients the 5-year progression-free survival rate was 92% (95% CI: 87%-94%) and the 5-year survival accounting for chronic myeloid leukemia deaths was 97% (95% CI: 94%-99%). Of the 309 patients allocated to low (n=199), intermediate (n=68) and high (n=42) risk groups by the EUTOS Long-Term Survival score, events (progression and/or death) occurred in 6.0%, 8.8% and 26.2%, respectively. Estimates of the 5-year progression-free survival rates according to these three risk groups were 96% (95% CI: 92%-98%), 88% (95% CI: 76%-95%) and 67% (95% CI: 48%-81%), respectively. Differences in progression-free survival according to these risk groups were highly significant (P<0.0001, overall). The EUTOS Long-Term Survival score showed better differentiation of progression-free survival than the Sokal (<45 years), Euro and EUTOS scores in children and adolescents with chronic myeloid leukemia and should be considered in therapeutic algorithms. (Trial registered at: www.clinicaltrials.gov NCT01281735).
650    _2
$a mladiství $7 D000293
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a progrese nemoci $7 D018450
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a chronická myeloidní leukemie $x diagnóza $x farmakoterapie $x epidemiologie $x mortalita $7 D015464
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prognóza $7 D011379
650    _2
$a registrace $7 D012042
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Guilhot, Joëlle $u Inserm CIC 1402, University Hospital, Poitiers, France.
700    1_
$a Suttorp, Meinolf $u Department of Pediatrics, University Hospital Carl Gustav Carus, Dresden, Germany.
700    1_
$a Güneş, Adalet Meral $u Department of Pediatric Hematology, Uludağ University Hospital, Görükle Bursa, Turkey.
700    1_
$a Sedlacek, Petr $u Department of Pediatric Hematology-Oncology, University Hospital Motol, Charles University, Prague, Czech Republic.
700    1_
$a De Bont, Eveline $u Department of Pediatric Oncology/Hematology, University Medical Center Groningen, University of Groningen, the Netherlands, and Dutch Childhood Oncology Group, the Hague, the Netherlands.
700    1_
$a Li, Chi Kong $u Department of Pediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, China.
700    1_
$a Kalwak, Krzysztof $u Department of Pediatric Hematology Oncology and Transplantation, Wroclaw Medical University, Poland.
700    1_
$a Lausen, Birgitte $u Department of Pediatrics, Rigshospitalet, University Hospital, Copenhagen, Denmark.
700    1_
$a Culic, Srdjana $u Department of Pediatric Hematology Oncology Immunology and Medical Genetics, Clinical Hospital Split, Croatia.
700    1_
$a Dworzak, Michael $u Children's Cancer Research Institute and St. Anna Children's Hospital, Vienna, Austria.
700    1_
$a Kaiserova, Emilia $u Department of Pediatric Oncology of University Children's Hospital, Bratislava, Slovakia.
700    1_
$a De Moerloose, Barbara $u Department of Pediatrics, Ghent University Hospital, Belgium.
700    1_
$a Roula, Farah $u Department of Pediatrics, Saint George Hospital University Medical Center, Beirut, Lebanon.
700    1_
$a Biondi, Andrea $u Department of Pediatrics, University of Milano-Bicocca, San Gerardo Hospital, Fondazione MBBM, Monza, Italy.
700    1_
$a Baruchel, André $u Department of Pediatric Hematology, Robert Debré Hospital, Paris, France.
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 102, č. 10 (2017), s. 1704-1708
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28838993 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180716095825 $b ABA008
999    __
$a ok $b bmc $g 1316841 $s 1021631
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 102 $c 10 $d 1704-1708 $e 20170824 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace